TNFRSF8 and lymphoma: In addition to its use in isolation, anti-CD30 CAR-T has also been investigated as consolidation following autologous stem cell transplantation using carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning in patients with high-risk CD30+ lymphomas.